Norvasc: Effective Blood Pressure Control for Cardiovascular Health
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.84 | $50.20 (0%) | 🛒 Add to cart |
| 90 | $0.77 | $75.30 $69.28 (8%) | 🛒 Add to cart |
| 120 | $0.73 | $100.41 $87.35 (13%) | 🛒 Add to cart |
| 180 | $0.69 | $150.61 $123.50 (18%) | 🛒 Add to cart |
| 270 | $0.66 | $225.91 $177.72 (21%) | 🛒 Add to cart |
| 360 | $0.65
Best per pill | $301.22 $232.94 (23%) | 🛒 Add to cart |
| Product dosage: 2.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 180 | $0.34 | $61.25 (0%) | 🛒 Add to cart |
| 270 | $0.32 | $91.87 $85.35 (7%) | 🛒 Add to cart |
| 360 | $0.30
Best per pill | $122.50 $109.44 (11%) | 🛒 Add to cart |
Norvasc (amlodipine besylate) is a widely prescribed calcium channel blocker indicated for the management of hypertension and chronic stable angina. As a first-line antihypertensive agent, it functions by relaxing blood vessels, allowing blood to flow more efficiently and reducing cardiac workload. Its long half-life supports consistent 24-hour blood pressure control with once-daily dosing, making it a cornerstone therapy in cardiovascular risk management. Clinicians favor Norvasc for its predictable pharmacokinetics, favorable safety profile, and evidence-based efficacy in diverse patient populations.
Features
- Active ingredient: Amlodipine besylate
- Available in 2.5 mg, 5 mg, and 10 mg oral tablets
- Belongs to the dihydropyridine calcium channel blocker class
- Long elimination half-life (~30–50 hours)
- Once-daily dosing regimen
- FDA-approved for hypertension and angina
Benefits
- Provides sustained 24-hour blood pressure reduction with single daily dosing
- Decreases frequency of angina episodes and reduces nitrate use in patients with coronary artery disease
- Lowers risk of cardiovascular events such as myocardial infarction and stroke in hypertensive patients
- Exhibits minimal effect on heart rate and cardiac conduction
- Suitable for use in patients with asthma, diabetes, or peripheral vascular disease
- Well-tolerated with a low discontinuation rate due to adverse effects
Common use
Norvasc is primarily prescribed for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents. It is also indicated for the management of chronic stable angina and vasospastic (Prinzmetal’s) angina. Clinicians may consider Norvasc for off-label uses such as Raynaud’s phenomenon, though such applications require careful medical supervision. The medication is commonly incorporated into treatment plans for patients requiring gradual blood pressure control without significant heart rate effects.
Dosage and direction
The recommended initial dose for hypertension in adults is 5 mg once daily, which may be increased to a maximum dose of 10 mg daily based on therapeutic response. For angina, the starting dose is typically 5–10 mg daily, with most patients maintained on 10 mg. Small or frail patients, those with hepatic impairment, or those taking concomitant antihypertensives may initiate therapy at 2.5 mg daily. Norvasc may be administered with or without food, preferably at the same time each day to maintain consistent plasma concentrations. Dose adjustments should occur at 7–14 day intervals to allow full therapeutic effect.
Precautions
Patients should be monitored for peripheral edema, which is dose-related and more common at higher doses. Blood pressure should be regularly assessed, particularly during dosage titration. Use with caution in patients with severe aortic stenosis due to potential reduction in coronary perfusion. Hepatic impairment may increase amlodipine concentrations, requiring dose reduction. Patients should avoid abrupt discontinuation, as rebound hypertension or angina exacerbation may occur. Elderly patients may exhibit increased sensitivity and require lower initial dosing.
Contraindications
Norvasc is contraindicated in patients with known hypersensitivity to amlodipine or any component of the formulation. It should not be administered to patients experiencing cardiogenic shock or clinically significant hypotension (systolic pressure <90 mmHg). The medication is contraindicated in those with unstable angina except when chronic stable angina is properly diagnosed. Concomitant use with strong CYP3A4 inhibitors in patients with hepatic impairment is not recommended.
Possible side effect
Common adverse reactions include peripheral edema (dose-dependent), headache, fatigue, nausea, abdominal pain, and dizziness. Less frequently reported effects include palpitations, flushing, somnolence, and gingival hyperplasia. Serious but rare side effects may include symptomatic hypotension, worsening angina, myocardial infarction, and arrhythmias. Allergic reactions including rash, pruritus, and urticaria have been reported. Elevations in liver enzymes typically resolve with discontinuation.
Drug interaction
Moderate interactions occur with simvastatin (limit to 20 mg daily). CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) may increase amlodipine concentrations. Concurrent use with other antihypertensives may potentiate blood pressure-lowering effects. Calcium supplements may reduce Norvasc efficacy. Use with sildenafil or other PDE5 inhibitors may increase hypotensive effects. Monitor cyclosporine levels when co-administered, as amlodipine may increase concentrations.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is nearly time for the next scheduled dose, the missed dose should be skipped. Patients should not double the dose to make up for a missed administration. Consistent daily dosing is important for maintaining therapeutic blood levels, but occasional missed doses are unlikely to significantly impact overall blood pressure control due to the drug’s long half-life.
Overdose
Symptoms of overdose may include pronounced hypotension with possible reflex tachycardia and peripheral vasodilation. Bradycardia, shock, and cardiac arrest have been reported in severe cases. Management involves cardiovascular monitoring with elevation of lower extremities and administration of intravenous fluids. Vasopressors such as dopamine or norepinephrine may be considered for refractory hypotension. Calcium gluconate administration (10% solution) may help reverse calcium channel blockade effects. Gastric lavage may be beneficial if performed soon after ingestion.
Storage
Store at controlled room temperature (20–25°C or 68–77°F) with excursions permitted between 15–30°C (59–86°F). Protect from light and moisture. Keep in the original container with the lid tightly closed. Do not store in bathroom cabinets where humidity levels may fluctuate. Keep out of reach of children and pets. Properly discard any expired or unused medication according to FDA-recommended disposal guidelines.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Norvasc is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to therapy may vary, and patients should follow their prescribing physician’s instructions regarding dosage, administration, and monitoring. Never adjust dosage or discontinue medication without consulting your healthcare provider.
Reviews
Clinical studies demonstrate Norvasc’s efficacy in reducing systolic and diastolic blood pressure by 12–15 mmHg and 6–8 mmHg respectively at 10 mg daily dose. Meta-analyses of antihypertensive trials show consistent 24-hour coverage with smooth blood pressure reduction. The ASCOT-BPLA trial established its cardiovascular protective benefits in combination therapy. Patient satisfaction surveys indicate high adherence rates due to once-daily dosing and generally favorable side effect profile compared to other antihypertensive classes. Long-term follow-up studies confirm maintained efficacy without development of tolerance.